bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.07.09.602649

The regulatory grammar of human promoters uncovered by MPRA-trained deep learning

Abstract

One of the major challenges in genomics is to build computational models that accurately predict genome-wide gene expression from the sequences of regulatory elements. At the heart of gene regulation are promoters, yet their regulatory logic is still incompletely understood. Here, we report PARM, a cell-type specific deep learning model trained on specially designed massively parallel reporter assays that query human promoter sequences. PARM requires [~]1,000 times less computational power than state-of-the-art technology, and reliably predicts autonomous promoter activity throughout the genome from DNA sequence alone, in multiple cell types. PARM can even design purely synthetic strong promoters. We leveraged PARM to systematically identify binding sites of transcription factors (TFs) that are likely to contribute to the activity of each natural human promoter. We uncovered and experimentally confirmed striking positional preferences of TFs that differ between activating and repressive regulatory functions, as well as a complex grammar of motif-motif interactions. For example, many, but not all, TFs act as repressors when their binding motif is located near or just downstream of the transcription start site. Our approach lays the foundation towards a deep understanding of the regulation of human promoters by TFs. HighlightsO_LICausality-trained deep learning model PARM captures regulatory grammar of human promoters C_LIO_LIPARM is highly economical, both experimentally and computationally C_LIO_LITranscription factors have different preferred positions for their regulatory activity C_LIO_LIMany (but not all) transcription factors act as repressors when binding downstream of transcription start sites C_LI

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Barbadilla-Martinez, L., Klaassen, N. H., Fransceschini-Santos, V., Breda, J., Hernandez-Quiles, M., van Lieshout, T., Urzua, C., Yucel, H., Boi, M. C. L., Hermana-Garcia, C., Gregoricchio, S., Zwart, W. H., Voest, E., Franke, L., Vermeulen, M., de Ridder, J., van Steensel, B.. 2024-07-13. The regulatory grammar of human promoters uncovered by MPRA-trained deep learning. https://doi.org/10.1101/2024.07.09.602649

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗